Full-Time

Lab Systems Manager

Updated on 9/13/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Evening or night shifts may be required, including second- or third-shift schedules.

Bachelor's

Category
IT Operations (1)
Required Skills
GMP
Public Speaking
Customer Service

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Any degree with 8–13 years of experience in Business, Engineering, Information Technology, or a related field.
  • Hands-on experience working with computer systems from inception through deployment and maintenance, with general to good understanding of quality processes, laboratory, benchtop, and manufacturing systems.
  • General information technology architecture and hardware knowledge, with general understanding of project management, customer service, and conflict resolution.
  • Experience applying technology best-practice methodologies such as Scaled Agile Framework and Information Technology Infrastructure Library.
  • Deep understanding of the biopharmaceutical industry and Good Manufacturing Practice-regulated environments.
  • Experience with leadership in a pharmaceutical or technology organization.
  • Extensive experience with the software development lifecycle.
  • Experience using and adopting the Scaled Agile Framework.
  • Established business partnerships and information systems governance practices involving senior business stakeholders.
  • Broad working knowledge of key information systems domains and layers.
  • ITIL certification is preferred.
  • Scaled Agile Framework for Teams certification.
  • Willingness and ability to work evening or night shifts, including second- or third-shift schedules, as required by business needs.
Responsibilities
  • Serve as System Owner for multiple laboratory systems, ensuring reliability, data integrity, and continuous Good Manufacturing Practice compliance.
  • Execute configuration and system changes under formal change control while maintaining the validated state.
  • Ensure system documentation, configuration records, and validation deliverables remain inspection-ready.
  • Provide ancillary support for internal and external audits, inspections, and data integrity assessments.
  • Maintain alignment with global computer systems validation and Annex 11 / 21 CFR Part 11 requirements.
  • Provide complex functional support to the RunOps team.
  • Facilitate escalation and resolution of complex system issues with the global product owner or application vendor.
  • Collaborate with business performance, Operational Excellence/Continuous Improvement analysts, site project managers, and scrum masters to schedule, communicate, and implement site changes.
  • Provide subject-matter-expert input for root-cause analysis and implement corrective and preventive actions to ensure system reliability.
  • Monitor system performance and proactively identify opportunities to improve system efficiency and user experience.
  • Develop and lead a highly talented team delivering operational support.
Desired Qualifications
  • Strong analytical, critical-thinking, and decision-making abilities.
  • Ability to work effectively in a fast-paced, dynamic environment.
  • Strong transformation and change-management experience.
  • Excellent collaboration, communication, and interpersonal skills for managing stakeholder relationships and building partnerships.
  • High degree of initiative and self-motivation.
  • Ability to manage multiple priorities successfully.
  • Team-oriented approach focused on achieving team goals.
  • Strong presentation and public-speaking skills.
  • Excellent analytical and troubleshooting skills.
  • Ability to work effectively with global, virtual teams.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.